A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Cystic Fibrosis

In brief

This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.

Key facts

Study ID
NCT06237335
Run by
ReCode Therapeutics
People needed
192
Starts
2024-02-01
Expected to finish
2026-12-31
Last updated by the study team
2026-01-16

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.